Table 4: Schedule of Selected FDA-approved Psychotropic Medications for Children (Continued) Generic and Brand Names FDA-Approved Indications and Dosing Zoloft (Sertraline)
OCD: <6 years: Safety and efficacy not established; 6–12 years: 25 mg PO qDay initially; 12–17 years: 50 mg PO qDay initially; may increase by 50 mg qDay at 1-week intervals to no more than 200 mg qDay; give qHS if somnolence experienced MDD: ≥12 years: 10 mg PO qDay; may increase the dose after at least 3 weeks; not to exceed 20 mg/day Depression: Adolescents initial: 25–50 mg/day PO in divided doses; increase gradually to 100 mg/day in divided doses OCD: <10 years: Safety and efficacy not established; ≥10 years: 25 mg PO qDay initially; gradually increase to maximum 3 mg/kg/day or 100 mg/day, whichever is less; may further increase to maximum 3 mg/kg/day or 200 mg/day, whichever is less; may give as single dose qHS once tolerated Adolescents; <12 years: Safety and efficacy not established; Initial: 25–50 mg PO qDay; may gradually increase if needed to 100 mg/day PO qDay or divided q8–12hr; No more than 150 mg/day
Lexapro (Escitalopram)
Elavil, Levate (Amitriptyline)
Anafranil (Clomipramine)
Norpramin, Desipramine
Vivactil (Protriptyline)
Depression: <12 years: Safety and efficacy not established; ≥12 years: 15–20 mg PO qDay
Antipsychotics (First Generation) Abilify, Abilify Maintena, Aristada (Aripiprazole)
Schizophrenia: 13–17 years: 2 mg/day PO initially; increase to 5 mg/day after 2 days; increase to recommended dosage of 10 mg/day after additional 2 days; may subsequently be increased by 5 mg/day; maintenance: 10–30 mg/day Bipolar mania: Acute manic or mixed episodes, either as monotherapy or as an adjunct to lithium or valproate; 10–17 years: 2 mg/day PO initially; increase to 5 mg/day after 2 days; increase to recommended dosage of 10 mg/day after additional 2 days; may subsequently be increased by 5 mg/day; maintenance: 10–30 mg/day Autism: Irritability associated with autistic disorder; <6 years: Safety and efficacy not established; 6–17 years: 2 mg/day PO initially; increase gradually at intervals ≥1 week to target dosage of 5 mg/day; may gradually be further increased PRN to 10 mg/day or higher; not to exceed 15 mg/day Schizophrenia, psychosis/sedation: 12 years: Moderate disease, 0.5–2 mg PO q8–12 hr initially; severe disease: 3–5 mg PO q8–12 hr; not to exceed 30 mg/day Tourette disorder: 12 years: 0.5–2 mg PO q8–12 hr initially; if severe symptoms necessitate increased dosage, titrate upward to 3–5 mg PO q8–12 hr; if patient remains inadequately controlled, daily doses up to 100 mg have been used (safety not determined) Behavioral disorders: <3 years: Safety and efficacy not established; 3-12 years: 0.5 mg/day PO initially; dose increased PRN by 0.5 mg every 5–7 days until therapeutic effect achieved, then reduced to the lowest effective maintenance level of 0.05–0.075 mg/kg/day PO divided q8–12 hr Acute agitation: 12 years: 0.5–3 mg PO, repeated in 1 hour PRN; alternatively, 2–5 mg IM, repeated in 1 hr PRN Schizophrenia: 12 years; mild–moderate—initial: 2 mg PO q8 hr; may increase to 15 mg/day; severe—initial 5 mg PO q12 hr; maintenance—20–30 mg/day; no more than 60 mg/day PO divided q8–12 hr Tourette disorder: <2 years: safety and efficacy not established; 2–12 years—initial: 0.05 mg/ kg/day PO qHS; can be increased q3Days to 0.2 mg/kg/day PO qHS; maintenance dose: 2–4 mg/day; not to exceed 10 mg/day; >12 years—initial: 1–2 mg PO qDay; increase every other day; not to exceed 10 mg/day; maintenance: <0.2 mg/day or 10 mg/day—choose lowest dose Schizophrenia: 12 years; hospitalized patients: 8–16 mg PO q6–12hr; hospitalized patients: Not to exceed 64 mg/day divided q6–12hr; outpatients: 4–8mg PO q8hr; reduce as soon as possible to the minimum effective dose Schizophrenia : <12 years: Safety and efficacy not established; ≥12 years (<51 kg): 3 mg/day PO initially; may be increased if necessary in increments of 3 mg/day at intervals ≥5 days; not to exceed 6 mg/day; ≥12 years (≥51 kg): 3 mg/day PO initially; may be increased if necessary in increments of 3 mg/day at intervals ≥5 days; not to exceed 12 mg/day
Haldol, Haldol Decanoate, Haloperidol LA, Peridol, haloperidol
Navane, thiothixene
Orap (Pimozide)
Trilafon (Perphenazine)
Antipsychotics (Second Generation) Invega, Invega Sustenna, Invega Trinza, (Paliperidone)
EliteLearning.com/Psychology
Book Code: PYFL4024
Page 179
Powered by FlippingBook